Tri-arginine insulins
AssigneeEli Lilly and Company
InventorsJames A. Hoffmann, Peter K. Lambooy
Life of this patent
Estimating the term…
Abstract
This invention relates to human insulin analogs (tri-arg insulins) and includes two enzymatic methods for producing tri-arg insulins. These compounds can be formulated as a soluble entity up to pH 6.1 and have prolonged hypoglycemic activity. Tri-arg insulins have the basic structure of natural human insulin plus three additional arginine residues. Two of the three additional Arg residues are located in tandem at the carboxy terminus of the insulin B-chain, and the third Arg residue is located at the amino terminus of the insulin A-chain. Tri-arg insulin analogs, having certain amino acid substitutions at the B3, B10 and A21 positions, are within the instant invention.
Claims4
Split(64) proinsulin-tri-arg-analog consisting of human proinsulin wherein the B3 and A21 residues are selected from the group consisting of Ala, Arg, Asx, Cys, Glx, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val, the B10 residue is selected from the group consisting of His, Asp or Glu, and wherein the amide bond between Lys-64 and Arg-65 is broken, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.